Overview

Efficacy and Safety of Risedronate Therapy Administered 35 mg Once A Week in Men With Osteoporosis

Status:
Completed
Trial end date:
2007-05-01
Target enrollment:
0
Participant gender:
Male
Summary
Two year study to determine the safety and efficacy of weekly 35 mg Risedronate doses in men with osteoporosis followed by a two year follow-up study.
Phase:
Phase 3
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Warner Chilcott
Collaborator:
Sanofi
Treatments:
Etidronic Acid
Risedronate Sodium
Risedronic Acid
Criteria
Inclusion Criteria:

- Documented osteoporosis of the femoral neck and lumbar spine

Exclusion Criteria:

- BMI greater than or equal to 35